GENMAB A/S financials

Also U.S.-listed. GENMAB A/S is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: GMAB — Genmab A/S

GENMAB A/S

Country: DK Reporting currency: USD Latest annual report: 2026-06-30

LEI: 529900MTJPDPE4MHJ122

Source filing ↗

Financial statements (USD, as reported — unscaled; 94 line items across 3 annual periods)

Line item	2026	2025-12-31	2025-06-30
Income statement
Revenue	$2.05B	—	$1.64B
Cost of sales	$149.0M	—	$99.0M
Operating expenses	$1.50B	—	$1.09B
Operating profit (EBIT)	$555.0M	—	$548.0M
Finance costs	$289.0M	—	$134.0M
Profit before tax	$369.0M	—	$667.0M
Income tax expense	$13.0M	—	$136.0M
Profit for the year	$356.0M	—	$531.0M
Total comprehensive income	$140.0M	—	$547.0M
Per share
Basic EPS	$5.78	—	$8.47
Diluted EPS	$5.73	—	$8.45
Free cash flow / share	$0.76	—	$5.20
Cash flow statement
Cash generated from operations	$317.0M	—	$609.0M
Net cash from operating activities	$54.0M	—	$349.0M
Income taxes paid	$96.0M	—	$315.0M
Net cash from investing activities	-$7.0M	—	-$17.0M
Purchase of PP&E (capex)	$7.0M	—	$22.0M
Purchase of intangibles	$1.0M	—	$18.0M
Net cash from financing activities	-$252.0M	—	-$419.0M
Repayments of borrowings	$125.0M	—	$0
Lease liability payments	$9.0M	—	$6.0M
Net change in cash	-$205.0M	—	-$87.0M
Balance sheet
Total assets	$12.52B	$12.87B	—
Non-current assets	$9.71B	$9.99B	—
Property, plant & equipment	$137.0M	$153.0M	—
Right-of-use assets	$117.0M	$127.0M	—
Intangible assets & goodwill	$355.0M	$355.0M	—
Current assets	$2.80B	$2.88B	—
Inventories	$18.0M	$18.0M	—
Trade & other receivables	$1.21B	$1.11B	—
Cash & equivalents	$1.50B	$1.72B	$1.30B
Total equity	$5.96B	$5.85B	$5.30B
Non-current liabilities	$5.42B	$5.60B	—
Long-term borrowings	$4.84B	$5.00B	—
Lease liabilities (non-current)	$120.0M	$134.0M	—
Current liabilities	$1.14B	$1.43B	—
Short-term borrowings	$294.0M	$273.0M	—
Lease liabilities (current)	$18.0M	$18.0M	—
Deferred tax liabilities	$364.0M	$364.0M	—
Derived metrics
Free cash flow	$47.0M	—	$327.0M
Operating margin	27.1%	—	33.4%
Net margin	17.4%	—	32.4%
Return on equity	6.0%	—	10.0%
Cash conversion ratio	0.15×	—	0.66×
Capex coverage	7.71×	—	15.86×
Other reported items
Adjustments For Amortisation Expense	$25.0M	—	$7.0M
Adjustments For Decrease Increase In Inventories	$0	—	-$4.0M
Adjustments For Decrease Increase In Trade and Other Receivables	-$101.0M	—	-$77.0M
Adjustments For Depreciation Expense	$30.0M	—	$25.0M
Adjustments For Finance Costs	$289.0M	—	$134.0M
Adjustments For Finance Income	$103.0M	—	$253.0M
Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss	$1.0M	—	$1.0M
Adjustments For Increase Decrease In Contract Liabilities	-$10.0M	—	$0
Adjustments For Increase Decrease In Other Operating Payables	-$269.0M	—	$51.0M
Adjustments For Sharebased Payments	$86.0M	—	$58.0M
Balances With Banks	$1.50B	—	$1.17B
Current Contract Liabilities	$21.0M	$24.0M	—
Current Tax Assets Current	$68.0M	$40.0M	—
Current Tax Liabilities Current	$0	$43.0M	—
Decrease Increase Through Tax On Sharebased Payment Transactions	$23.0M	—	$14.0M
Deferred Tax Assets	$173.0M	$171.0M	—
Effect of Exchange Rate Changes On Cash and Cash Equivalents	-$7.0M	—	$3.0M
Equity and Liabilities	$12.52B	$12.87B	—
Finance Income	$103.0M	—	$253.0M
Gains Losses On Cash Flow Hedges Before Tax	$10.0M	—	$0
Gains Losses On Cash Flow Hedges Net of Tax	$10.0M	—	$0
Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income	$0	—	$0
Increase Decrease Through Exercise of Warrants Equity	$3.0M	—	$7.0M
Increase Decrease Through Sharebased Payment Transactions	$86.0M	—	$55.0M
Intangible Assets Other Than Goodwill	$8.87B	$9.12B	—
Interest Paid Classified As Operating Activities	$191.0M	—	$0
Interest Received Classified As Operating Activities	$27.0M	—	$58.0M
Issued Capital	$10.0M	$10.0M	—
Liabilities	$6.56B	$7.03B	—
Noncurrent Contract Liabilities	$88.0M	$95.0M	—
Noncurrent Investments Other Than Investments Accounted For Using Equity Method	$36.0M	$37.0M	—
Noncurrent Receivables	$24.0M	$22.0M	—
Other Comprehensive Income	-$216.0M	—	$16.0M
Other Comprehensive Income Net of Tax Exchange Differences On Translation	-$226.0M	—	$16.0M
Other Current Payables	$807.0M	$1.07B	—
Other Noncurrent Payables	$5.0M	$5.0M	—
Other Reserves	-$397.0M	-$181.0M	—
Payments For Debt Issue Costs	$2.0M	—	$0
Payments To Acquire Or Redeem Entitys Shares	$96.0M	—	$406.0M
Proceeds From Exercise of Warrants	$3.0M	—	$7.0M
Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method	$5.0M	—	$0
Purchase of Investments Other Than Investments Accounted For Using Equity Method	$4.0M	—	$3.0M
Purchase of Treasury Shares	$96.0M	—	$430.0M
Reduction of Issued Capital	—	—	$0
Research and Development Expense	$899.0M	—	$723.0M
Retained Earnings	$4.42B	$4.10B	—
Selling General and Administrative Expense	$371.0M	—	$270.0M
Share Premium	$1.92B	$1.92B	—
Shortterm Investments Classified As Cash Equivalents	$0	—	$122.0M

Methodology

Every line item above is a fact tagged in GENMAB A/S's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (USD), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.